T3D Therapeutics

T3D Therapeutics is a clinical-stage drug development company engaged in the development of T3D-959, a small molecule, orally administered, brain-penetrant dual nuclear receptor agonist designed to improve glucose and lipid metabolic dysfunction present in Alzheimer's disease (AD) and other neurodegenerative diseases.